{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:24:18Z","timestamp":1757618658618,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014234","name":"Korean Society of Nephrology","doi-asserted-by":"crossref","award":["Korean Society of Nephrology (2021)"],"award-info":[{"award-number":["Korean Society of Nephrology (2021)"]}],"id":[{"id":"10.13039\/501100014234","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","award":["Soonchunhyang University"],"award-info":[{"award-number":["Soonchunhyang University"]}],"id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fabry disease (FD) is an X-linked lysosomal storage disease caused by a mutation of the gene that encodes the \u03b1-galactosidase A enzyme. Treatment for FD is based on an enzyme replacement therapy (ERT), such as agalsidase-\u03b2, agalsidase-\u03b1, and migalastat. However, studies analyzing effects and outcomes of ERT in FD patients in South Korea are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>Treatment status and clinical outcomes of patients with FD in South Korea were investigated using data from the National Health Insurance Service (NHIS). The NHIS provides a comprehensive range of data across the entire Korean population, enabling an in-depth analysis of clinical outcomes associated with FD, including coronary composite heart disease, cerebrovascular disease, end-stage kidney disease (ESKD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 228 patients with FD were discovered. The diagnosis was earlier in males (<jats:italic>n<\/jats:italic>\u2009=\u2009120) than in females (<jats:italic>n<\/jats:italic>\u2009=\u2009108). Almost 90% of patients were treated only with intravenous agalsidase-\u03b2 or -\u03b1. A total of 15 patients switched from agalsidase to migalastat. All clinical outcomes manifested at an earlier age in males than in females. Particularly, ESKD was more prevalent in males, both before and after diagnosis of FD. Patients who had ESKD at the time of FD diagnosis exhibited a higher hazard ratio (HR) for mortality (HR: 5.01, 95% confidence interval: 1.44\u201317.46).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study showed the current treatment status and clinical outcomes in patients with FD in South Korea. Prior to the diagnosis of FD, a considerable number of patients had already reached ESKD, suggesting a lack of awareness of FD among clinicians. Given the higher mortality rate observed in patients with FD and accompanying ESKD, the necessity to improve awareness of FD is highlighted to facilitate early diagnosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03863-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:29:13Z","timestamp":1752154153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current treatment status of fabry disease in South Korea: a longitudinal National health insurance service data-based study"],"prefix":"10.1186","volume":"20","author":[{"given":"DoHyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samel","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Hui","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunyong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-2138","authenticated-orcid":false,"given":"Young Joo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"3863_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3863_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23876\/j.krcp.23.125","volume":"43","author":"JH Shin","year":"2024","unstructured":"Shin JH, Kim SH. Screening and diagnosis of Fabry disease in chronic kidney disease: the important role of globotriaosylsphingosine. Kidney Res Clin Pract. 2024;43(1):1\u20135.","journal-title":"Kidney Res Clin Pract"},{"issue":"9","key":"3863_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57(9):1093\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3863_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke. 2009;40(3):788\u201394.","journal-title":"Stroke"},{"issue":"3","key":"3863_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry registry. Nephrol Dial Transpl. 2010;25(3):769\u201375.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"3863_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of Recombinant human alpha-galactosidase A replacement therapy in fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"3863_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-Stahl E, Hughes DA, Kampmann C, Mehta AB, et al. Twenty years of the Fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17(1):238.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3863_CR8","doi-asserted-by":"publisher","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","volume":"139","author":"C Wanner","year":"2023","unstructured":"Wanner C, Ortiz A, Wilcox WR, Hopkin RJ, Johnson J, Ponce E, et al. Global reach of over 20 years of experience in the patient-centered Fabry registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023;139(3):107603.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3863_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443\u20139.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"3863_CR10","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2215\/CJN.01820217","volume":"12","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, Tondel C, Leh S, Larsen KK, Houge G, Davidsen ES, et al. Long-Term Dose-Dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc Nephrol. 2017;12(9):1470\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"3863_CR11","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neusser LP, Rudnicki M, Nordbeck P, Canaan-Kuhl S, Nowak A, et al. Dose-Dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3863_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/jhg.2016.78","volume":"61","author":"JH Kim","year":"2016","unstructured":"Kim JH, Lee BH, Hyang Cho J, Kang E, Choi JH, Kim GH, et al. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet. 2016;61(11):923\u20139.","journal-title":"J Hum Genet"},{"key":"3863_CR13","doi-asserted-by":"crossref","unstructured":"Yang A, Kim S, Choi YJ. Impact of nontreatment duration and keratopathy on major adverse cardiovascular events in Fabry disease: A nationwide cohort study. J Clin Med. 2024;13(2).","DOI":"10.3390\/jcm13020479"},{"issue":"1","key":"3863_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4093\/dmj.2016.40.1.79","volume":"40","author":"YH Lee","year":"2016","unstructured":"Lee YH, Han K, Ko SH, Ko KS, Lee KU, Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes A. Data analytic process of a nationwide Population-Based study using National health information database established by National health insurance service. Diabetes Metab J. 2016;40(1):79\u201382.","journal-title":"Diabetes Metab J"},{"key":"3863_CR15","doi-asserted-by":"publisher","first-page":"882599","DOI":"10.3389\/fcvm.2022.882599","volume":"9","author":"S Park","year":"2022","unstructured":"Park S, Woo J, Leem S, Heo NH, Cho NJ, Gil H, et al. Transiently observed trace albuminuria on urine dipstick test is associated with All-Cause death, cardiovascular death, and incident chronic kidney disease: A National health insurance Service-National sample cohort in Korea. Front Cardiovasc Med. 2022;9:882599.","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"3863_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"2","key":"3863_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"3863_CR18","doi-asserted-by":"crossref","unstructured":"Reisin R, Perrin A, Garcia-Pavia P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. 2017;71(1).","DOI":"10.1111\/ijcp.12914"},{"issue":"7","key":"3863_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","volume":"53","author":"A Ortiz","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry registry. J Med Genet. 2016;53(7):495\u2013502.","journal-title":"J Med Genet"},{"issue":"23","key":"3863_CR20","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1136\/heartjnl-2020-317922","volume":"107","author":"M El Sayed","year":"2021","unstructured":"El Sayed M, Hirsch A, Boekholdt M, van Dussen L, Datema M, Hollak C, et al. Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease. Heart. 2021;107(23):1889\u201397.","journal-title":"Heart"},{"issue":"29","key":"3863_CR21","doi-asserted-by":"publisher","first-page":"e7387","DOI":"10.1097\/MD.0000000000007387","volume":"96","author":"JH Choi","year":"2017","unstructured":"Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: underdiagnosis of late-onset phenotype. Med (Baltim). 2017;96(29):e7387.","journal-title":"Med (Baltim)"},{"issue":"5","key":"3863_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, et al. Agalsidase Alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20(5):1132\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3863_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transpl. 2012;27(3):1042\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"3863_CR24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52(12):860\u20136.","journal-title":"J Med Genet"},{"issue":"1","key":"3863_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.23876\/j.krcp.22.087","volume":"43","author":"E Cho","year":"2024","unstructured":"Cho E, Park JT, Yoo TH, Kim SW, Park CW, Han SS, et al. Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea. Kidney Res Clin Pract. 2024;43(1):71\u201381.","journal-title":"Kidney Res Clin Pract"},{"issue":"5","key":"3863_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.23876\/j.krcp.22.235","volume":"42","author":"SJ Choi","year":"2023","unstructured":"Choi SJ, Kim SH, Lee MS, Park S, Cho E, Han SS, et al. A questionnaire survey on the diagnosis and treatment of Fabry nephropathy in clinical practice. Kidney Res Clin Pract. 2023;42(5):628\u201338.","journal-title":"Kidney Res Clin Pract"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03863-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:41:10Z","timestamp":1757220070000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03863-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3863"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03863-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Soonchunhyang University Cheonan Hospital (Cheonan, Korea) (IRB No: SCH-2022-08-052).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The requirement of informed consent was waived by the IRB due to a retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or non-financial competing interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}